Collection of Blood From Patients With Cancer

StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 351 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fields
  2. Re-verified, no change to tracked fields
  3. New version filed on ClinicalTrials.gov
  4. 32 versions Re-verified since Jul 9, 2025, no change to tracked fieldsv317-v348
  5. Study Status, Contacts/Locationsv316
  6. 14 versions Re-verified since Dec 4, 2024, no change to tracked fieldsv302-v315
National Cancer Institute (NCI)
963 trials monitored
See 78 trials at risk
Breast Cancer
5,486 trials monitored
See 312 trials at risk
Lung Cancer
4,822 trials monitored
See 269 trials at risk
Colorectal Cancer
3,420 trials monitored
See 164 trials at risk
and 2 more diseases
This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and older with cancer may participate. This study does not involve treatment. Participants will have about 50 ml (3 tablespoonfuls) of blood drawn. Depending on their condition, patients may be invited to enroll in a clinical research study involving chemotherapy, radiotherapy, or surgery. Additional 40-ml blood samples may be drawn during the course of treatment.
Trial Details
NCT Number NCT00034216
Lead Sponsor National Cancer Institute (NCI)
Conditions
(from sponsor)		 Prostate Cancer, Breast Cancer, Colon Cancer, Lung Cancer, Liver Cancer
Related terms Breast Neoplasms, Colonic Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Prostatic Neoplasms
Enrollment 1,750 participants
Start Date
Updated on ClinicalTrials.gov